Welcome to our dedicated page for Lumexa Imaging Holdings news (Ticker: LMRI), a resource for investors and traders seeking the latest updates and insights on Lumexa Imaging Holdings stock.
Lumexa Imaging Holdings, Inc. reports developments tied to its nationwide outpatient medical imaging platform. The company operates diagnostic imaging centers and provides radiology interpretation services, with imaging modalities that include MRI, CT, PET, X-ray, ultrasound and mammography.
Recurring LMRI news covers financial and operating results, conference-call schedules, de novo center openings, joint venture and health-system relationships, leadership appointments, investor conference participation and clinical quality initiatives. Company updates also address growth strategy, advanced imaging volume trends, payer-network activity, balance-sheet actions and the technology used to support patient engagement in radiology reporting.
Lumexa Imaging (NASDAQ: LMRI) announced that Jennifer L. Kemp, MD, Chair of its Center for Quality, was elected to the Radiological Society of North America (RSNA) Board of Directors and will serve as board liaison for government relations.
The company highlights Dr. Kemp's focus on patient-centered care and notes Lumexa's use of Scanslated AI-driven software, which has delivered over 2 million reports to patients and yielded a 99% positive survey response on likelihood to choose Lumexa centers.
Lumexa Imaging (NASDAQ: LMRI) set a company record by opening nine de novo outpatient imaging centers in 2025, including two centers that opened in December in Anderson, South Carolina and Cotswold, North Carolina. With these additions, Lumexa operates more than 185 centers across 13 states. Prior 2025 openings occurred in New York, South Carolina and Texas. Management said the de novo strategy targets high-growth MSAs and intends to continue expansion in 2026.
Lumexa Imaging (NASDAQ: LMRI) announced that CEO Caitlin Zulla and CFO Tony Martin will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with a presentation scheduled for 7:30 AM PST on Monday, January 12, 2026. A live webcast and presentation materials will be available at the company investor site: https://ir.lumexaimaging.com.
Lumexa Imaging (NASDAQ: LMRI) priced its initial public offering of 25,000,000 shares of common stock at $18.50 per share, with a 30‑day underwriter option for up to 3,750,000 additional shares.
The Common Stock is expected to begin trading on the Nasdaq Global Select Market under the symbol LMRI on December 11, 2025, and the offering is expected to close on December 12, 2025, subject to customary closing conditions. The registration statement on Form S‑1 was declared effective by the SEC on December 10, 2025.